β-blockers: A new and emerging treatment for melanoma;I β-bloccanti: Nuova prospettiva terapeutica per il melanoma

Recenti Progressi in Medicina

Volumn 103, Issue 1, 2012, Pages 11-16

  De Giorgi, Vincenzo ^a   Gandini, Sara ^b   Grazzini, Marta ^a   Benemei, Silvia ^c   Marchionni, Niccolò ^a   Geppetti, Pierangelo ^c  

^a UNIVERSITY OF FLORENCE   (Italy)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c Dipartimento di Farmacologia Preclinica e Clinica   (Italy)

Author keywords

blockers; Hypertension; Melanoma; Propranolol; Prostate cancer

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTINEOPLASTIC AGENT; PROPRANOLOL;

BREAST CANCER; CANCER GROWTH; CANCER INHIBITION; DISEASE FREE SURVIVAL; HUMAN; MELANOMA; OVERALL SURVIVAL; PROSTATE CANCER; REVIEW; RISK REDUCTION; ARTICLE; BREAST TUMOR; EVIDENCE BASED MEDICINE; FEMALE; MALE; PROSTATE TUMOR; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MALE; MELANOMA; PROPRANOLOL; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 84856775782     PISSN: 00341193     EISSN: 20381840     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Chapman PB, Hauschild A, Robert C, et al. BRIM-3 Study Group Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-16.
2. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-23.
3. Corrao G, Zambon A, Parodi A, Poluzzi E, Baldi I, Merlino L, et al. Discontinuation of and changes in drug therapy for hypertension among newly-treated patients: a population-based study in Italy. J Hypertens 2008; 26: 819-24. (Pubitemid 351354932)
4. Sipahi I, Debanne SM, Rowland DY, Simon DI, Fang JC. Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol 2010; 11: 627-36.
5. Bangalore S, Kumar S, Kjeldsen SE, et al. Messerli Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials. Lancet Oncol 2011; 12: 65-82.
6. Lands AM, Arnold A, McAuliff JP, Luduena FP, Brown TG. Differentiations of receptor systems activated by sympathomimetics amines. Nature 1967; 214: 597.
7. Bristow MR, Hershberger RE, Port JD, et al. Betaadrenergic pathways in non-failing and failing human ventricular myocardium. Circulation 1990; 82 (suppl. 1): 12-25.
8. Ursino MG, Vasina V, Raschi E, Crema F, De Ponti F. The beta3-adrenoceptor as a therapeutic target: current perspectives. Pharmacol Res 2009; 59: 221- 34.
9. Hardman JG, Limbird LE, Gilman AG (eds). Goodman & Gilman's. The pharmacological basis of therapeutics. New York: McGraw-Hill 2001.
10. Glaser R, Padgett DA, Litsky ML, et al. Stress-associated changes in the steady-state expression of latent Epstein-Barr virus: implications for chronic fatigue syndrome and cancer. Brain Behav Immun 2005; 19: 91-103. (Pubitemid 40138643)
11. Yang EV, Donovan EL, Benson DM, Glaser R. VEGF is differentially regulated in multiple myeloma-derived cell lines by norepinephrine. Brain Behav Immun 2008; 22: 318-23. (Pubitemid 351172710)
12. Antoni MH, Lutgendorf SK, Cole SW, et al. The influence of bio-behavioural factors on tumour biology: pathways and mechanisms. Nat Rev Cancer 2006; 6: 240-8. (Pubitemid 43292567)
13. Lutgendorf SK, Sood AK, Antoni MH. Host factors and cancer progression: biobehavioral signaling pathways and interventions. J Clin Oncol 2010; 28: 4094-9.
14. Thaker PH, Lutgendorf SK, Sood AK. The neuroendocrine impact of chronic stress on cancer. Cell Cycle 2007; 6: 430-3. (Pubitemid 46393445)
15. Entschladen F, Drell TL 4th, Lang K, et al. Tumour cell migration, invasion, and metastasis: Navigation by neurotransmitters. Lancet Oncol 2004; 5: 254-8.
16. Armaiz-Pena GN, Lutgendorf SK, Cole SW, et al. Neuroendocrine modulation of cancer progression. Brain Behav Immun 2009; 23: 10-15.
17. Sood AK, Armaiz-Pena GN, Halder J, et al. Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. J Clin Invest 2010; 120: 1515-23.
18. Maguiness SM, Frieden IJ. Infantile hemangiomas: a look back and future directions. Actas Dermosifiliogr 2009; 100 (suppl 1): 73-6.
19. Shyu KG, Wang BW, Hung HF, Chang CC, Shih DT. Mesenchymal stem cells are superior to angiogenic growth factor genes for improving myocardial performance in the mouse model of acute myocardial infarction. J Biomed Sci 2006; 13: 47-58. (Pubitemid 43162505)
20. Perron L, Bairati I, Harel F, Meyer F. Antihypertensive drug use and the risk of prostate cancer (Canada). Cancer Causes Control 2004; 15: 535-41. (Pubitemid 39070071)
21. Powe DG, Voss MJ, Zänker KS, Habashy HO, Green AR, Ellis IO, Entschladen F. Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget 2010; 1: 628-38.
22. Barron TI, Connolly RM, Sharp L, Bennett K, Visvanathan K. Beta blockers and breast cancer mortality: a population- based study. J Clin Oncol 2011; 29: 2635-44.
23. Melhem-Bertrandt A, Chavez-Macgregor M, Lei X, et al. Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol 2011; 29: 2645-52.
24. Yang EV, Kim SJ, Donovan EL, et al. Norepinephrine upregulates VEGF, IL-8, and IL-6 expression in human melanoma tumor cell lines: implications for stress-related enhancement of tumor progression. Brain Behav Immun 2009; 23: 267-75.
25. De Giorgi V, Grazzini M, Gandini S, et al. Treatment with &βετα;-blockers and reduced disease progression in patients with thick melanoma. Arch Intern Med 2011; 171: 779-81.
26. Lemeshow S, Sørensen HT, Phillips G, et al. β-blockers and survival among Danish patients with malignant melanoma: a population-based cohort study. Cancer Epidemiol Biomarkers Prev 2011; 20: 2273-9.